These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30858179)

  • 1. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers.
    Rao S; Du G; Hafner M; Subramanian K; Sorger PK; Gray NS
    J Biol Chem; 2019 May; 294(21):8664-8673. PubMed ID: 30858179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer.
    Lin SH; Zhang J; Giri U; Stephan C; Sobieski M; Zhong L; Mason KA; Molkentine J; Thames HD; Yoo SS; Heymach JV
    J Thorac Oncol; 2014 Jul; 9(7):965-973. PubMed ID: 24922006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.
    Sumi NJ; Ctortecka C; Hu Q; Bryant AT; Fang B; Remsing Rix LL; Ayaz M; Kinose F; Welsh EA; Eschrich SA; Lawrence HR; Koomen JM; Haura EB; Rix U
    Cell Chem Biol; 2019 Sep; 26(9):1240-1252.e11. PubMed ID: 31257184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
    Wu PK; Park JI
    Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Park JH; Choi YJ; Kim SY; Lee JE; Sung KJ; Park S; Kim WS; Song JS; Choi CM; Sung YH; Rho JK; Lee JC
    Oncotarget; 2016 Apr; 7(16):22005-15. PubMed ID: 26980747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
    Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
    Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.
    Pappano WN; Jung PM; Meulbroek JA; Wang YC; Hubbard RD; Zhang Q; Grudzien MM; Soni NB; Johnson EF; Sheppard GS; Donawho C; Buchanan FG; Davidsen SK; Bell RL; Wang J
    BMC Cancer; 2009 Sep; 9():314. PubMed ID: 19732452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
    Caunt CJ; Sale MJ; Smith PD; Cook SJ
    Nat Rev Cancer; 2015 Oct; 15(10):577-92. PubMed ID: 26399658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds.
    Chan JY; Hackel BJ; Yee D
    Mol Cancer Ther; 2017 Jul; 16(7):1324-1334. PubMed ID: 28468775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells.
    Chan JY; LaPara K; Yee D
    Oncogene; 2016 Aug; 35(32):4235-43. PubMed ID: 26876199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
    Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
    Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
    Martinelli E; Morgillo F; Troiani T; Ciardiello F
    Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
    Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
    Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.
    Tognon CE; Rafn B; Cetinbas NM; Kamura T; Trigo G; Rotblat B; Okumura F; Matsumoto M; Chow C; Davare M; Pollak M; Mayor T; Sorensen PH
    J Biol Chem; 2018 Aug; 293(32):12502-12515. PubMed ID: 29903916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
    Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun SY; He Y; Zhou W
    Lung Cancer; 2018 Sep; 123():36-43. PubMed ID: 30089593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polypharmacology-based ceritinib repurposing using integrated functional proteomics.
    Kuenzi BM; Remsing Rix LL; Stewart PA; Fang B; Kinose F; Bryant AT; Boyle TA; Koomen JM; Haura EB; Rix U
    Nat Chem Biol; 2017 Dec; 13(12):1222-1231. PubMed ID: 28991240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.